Erratum: Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials (The Lancet (2015) 386(10001) (1353–1361) (S0140673615609084) (10.1016/S0140-6736(15)60908-4));Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials

The Lancet

Volumn 386, Issue 10001, 2015, Pages 1353-1361

  Coleman, R ^b   Gray, R ^ah   Powles, T ^c,ah   Paterson, A ^d   Gnant, M ^e   Bergh, J ^k   Pritchard, K I ^l   Bliss, J ^m   Cameron, D ⁿ   Bradley, R ^ah   Pan, H ^o   Peto, R ^a,o   Burrett, J ^ah   Clarke, M ^ah   Davies, C ^ah   Duane, F ^ah   Evans, V ^o   Gettins, L ^ah   Godwin, J ^ah   Liu, H ^ah   McGale, P ^ah   Mackinnon, E ^ah   McHugh, T ^ah   James, S ^ah   Morris, P ^ah   Read, S ^ah   Taylor, C ^ah   Wang, Y ^ah   Wang, Z ^ah   Anderson, S ^f   Diel, I ^g   Gralow, J ^h   von Minckwitz, G ⁱ   Moebus, V ^j   Bartsch, R ^p   Dubsky, P ^p   Fesl, C ^p   Fohler, H ^p   Greil, R ^p   Jakesz, R ^p   Lang, A ^p   Luschin Ebengreuth, G ^p   Marth, C ^p   Mlineritsch, B ^p   Samonigg, H ^p   Singer, C F ^p   Steger, G G ^p   Stoger, H ^p   Olivotto, I ^q   Ragaz, J ^q   Christiansen, P ^r   Ejlertsen, B ^r   Ewertz, M ^r   Jensen, M B ^r   Moller, S ^r   Mouridsen, H T ^r   Eiermann, W ^s   Hilfrich, J ^s   Jonat, W ^s   Kaufmann, M ^s   Kreienberg, R ^s   Schumacher, M ^s   Blohmer, J U ⁱ   Costa, S D ⁱ   Eidtmann, H ⁱ   Gerber, B ⁱ   Jackisch, C ⁱ   Loibl, S ⁱ   Dafni, U ^t   Markopoulos, C ^t   Blomqvist, C ^u   Saarto, T ^u   Ahn, J H ^v   Jung, K H ^v   Perrone, F ^w   Bass, G ^x   Brown, A ^x   Bryant, J ^x   Costantino, J ^x   Dignam, J ^x   Fisher, B ^x   Geyer, C ^x   Mamounas, E P ^x   Paik, S ^x   Redmond, C ^x   Swain, S ^x   Wickerham, L ^x   Wolmark, N ^x   Hadji, P ^y   Hern, R ^c   Dowsett, M ^c   Makris, A ^c   Parton, M ^c   Pennert, K ^c   Smith, I E ^c   Yarnold, J R ^c   Clack, G ^z   Van Poznak, C ^z   Safra, T ^aa   Bell, R ^ab   Dodwell, D ^ab   Hinsley, S ^ab   Marshall, H C ^ab   Solomayer, E ^ab   Fehm, T ^ac   Lester, J ^b   Winter, M C ^b   Horsman, J M ^b   Aft, R ^ad   Brufsky, A M ^ae   Llombart, H A ^ae   Perez, E ^af   Ingle, J N ^af   Suman, V J ^af   Pritchard, K ^ah   Albain, K ^ah   Arriagada, R ^ah   Barlow, W ^ah   Bergsten Nordstrom, E ^ah   Boccardo, F ^ah   Buyse, M ^ah   Coates, A ^ah   Correa, C ^ah   Cuzick, J ^ah   Davidson, N ^ah   Di Leo, A ^ah   Forbes, J ^ah   Gelber, R ^ah   Gianni, L ^ah   Goldhirsch, A ^ah   Hayes, D ^ah   Hill, C ^ah   Ingle, J ^ah   Janni, W ^ah   Martin, M ^ah   Norton, L ^ah   Ohashi, Y ^ah   Piccart, M ^ah   Pierce, L ^ah   Raina, V ^ah   Ravdin, P ^ah   Robertson, J ^ah   Rutgers, E ^ah   Sparano, J ^ah   Viale, G ^ah   Wang, X ^ah   Whelan, T ^ah   Wilcken, N ^ah   Winer, E ^ah   Wood, W ^ah   more..

^a Oxford   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d TOM BAKER CANCER CENTRE   (Canada)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g Center for Holistic Gynecology   (Germany)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ German Breast Group   (Germany)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k KAROLINSKA INSTITUTE   (Sweden)

^l UNIVERSITY OF TORONTO   (Canada)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁿ UNIVERSITY OF EDINBURGH   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p Austrian Breast Cancer Study Group   (Austria)

^q BRITISH COLUMBIA CANCER AGENCY   (Canada)

^r Danish Breast Cancer Cooperative Group   (Denmark)

^s German Adjuvant Breast Group (GABG)   (Germany)

^t Hellenic Breast Surgeons Society   (Greece)

^u UNIVERSITY OF HELSINKI   (Finland)

^v Korean Liver Cancer Study Association   (South Korea)

^w NATIONAL CANCER INSTITUTE   (Italy)

^x NSABP Foundation Inc   (United States)

^y ProBONE study group   (Germany)

^z SABRE trial group   (United Kingdom)

^aa TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^ab UNIVERSITY OF LEEDS   (United Kingdom)

^ac SAARLAND UNIVERSITY   (Germany)

^ad WASHINGTON UNIVERSITY   (United States)

^ae Z FASTZO FAST and E ZO FAST study groups   (United States)

^af North Central Cancer Treatment Group Rochester   (United States)

^ag CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^ah NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ESTROGEN RECEPTOR; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; ESTROGEN BLOOD LEVEL; FOLLOW UP; FRACTURE; HUMAN; INTENTION TO TREAT ANALYSIS; MENOPAUSE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DRUG ADMINISTRATION; FEMALE; MORTALITY; PATHOLOGY;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS;

EID: 84944177030     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31454-X     Document Type: Erratum

References (30)

1. Weilbaecher KN,Guise TA,McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11: 411-25.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
3. Guo W. Concise review: breast cancer stem cells: regulatory networks,stem cell niches,and disease relevance. Stem Cells Transl Med 2014; 3: 942-48.
4. Mundy GR. Metastasis to bone: causes,consequences and therapeutic opportunities. Nat Rev Cancer 2003; 2: 584-93.
5. Thompson K,Roelofs AJ,Jauhiainen M,Monkkonen H,Monkkonen J,Rogers MJ. Activation of γδ T cells by bisphosphonates. Adv Exp Med Biol 2010; 658: 11-20.
6. Kanis J,Powles T,Paterson A,et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663-67.
7. Powles TJ,Paterson AE,McCloskey E,et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res Treat 2006; 8: R13,1-7.
8. Diel IJ,Jaschke A,Solomayer EF,et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long term follow up. Ann Oncol 2008; 19: 2007-11.
9. Gnant M,Mlineritsch B,Schippinger W,et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-91.
10. Coleman RE,de Boer R,Eidtmann H,et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-fast study): final 60-month results. Ann Oncol 2013; 24: 398-405.
11. Coleman RE,Cameron D,Dodwell D,et al,on behalf of the AZURE investigators. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014; 15: 997-1006.
12. Paterson AHG,Anderson SJ,Lembersky BC,et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre,placebo-controlled,randomised trial. Lancet Oncol 2012; 13: 734-42.
13. G,Mobus V,Schneeweiss A,et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-39.
14. Coleman RE,Marshall H,Cameron D,et al,on behalf of the AZURE investigators. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-405.
15. Coleman R,Gnant M,Morgan G,Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012; 104: 1059-67.
16. Hadji P,Coleman R,Gnant M,Green J. The impact of menopause on bone,zoledronic acid,and implications for breast cancer growth and metastasis. Ann Oncol 2012; 23: 2782-90.
17. Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer: worldwide evidence,1985-1990. Introduction and methods. Oxford: Oxford University Press,1990. http://www.ctsu. ox.ac.uk/reports/ebctcg-1990/index_html (accessed July 7,2015).
18. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
19. Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-84.
20. Hue TF,Cummings SR,Cauley JA,et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 2014; 174: 1550-57.
21. Chlebowski RT,Chen Z,Cauley JA,et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010; 28: 3582-90.
22. Rennert G,Pinchev M,Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010; 28: 3577-81.
23. Ottewell PD,Wang N,Meek J,et al. Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo. Clin Can Res 2014; 20: 2922-32.
24. Ottewell PD,Wang N,Brown HK,et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine-Related Cancer 2014; 21: 769-81.
25. Nicks KM,Fowler TW,Akel NS,et al. Bone turnover across the menopausal transition,the role of gonadal inhibins. Ann NY Acad Sci 2010; 1192: 153-60.
26. Cox TR,Rumney RMH,Schoof EM,et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015; 522: 106-10.
27. Kristensen B,Ejlertsen B,Mouridsen H,et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47: 740-46.
28. Brincker H,Westin J,Abildgaard N,et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma—a double blind placebo controlled trial. Br J Haematol 1998; 101: 280-86.
29. Gnant M,Mlineritsch B,Stoeger H,et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2014; 26: 313-20.
30. Rathbone EJ,Brown JE,Marshall HC,et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an Adjuvant Zoledronic Acid to Reduce Recurrence Trial subprotocol (BIG1/04). J Clin Oncol 2013; 31: 2685-92.